BTIG Reiterates Buy on Matinas BioPharma Hldgs, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Matinas BioPharma Hldgs (AMEX:MTNB) and maintained a price target of $3.
October 12, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BTIG analyst Julian Harrison has reiterated a 'Buy' rating on Matinas BioPharma Hldgs and maintained a price target of $3.
The reiteration of a 'Buy' rating and maintenance of a $3 price target by BTIG analyst Julian Harrison indicates a positive outlook for Matinas BioPharma Hldgs. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100